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Abstract
Tamoxifen is an endocrine therapy which is administered to up to 70% of all breast cancer patients with oestrogen
receptor alpha (ER𝛂) expression. Despite the initial response, most patients eventually acquire resistance to the
drug. MicroRNAs (miRNAs) are a class of small non-coding RNAs which have the ability to post-transcriptionally
regulate genes. Although the role of a few miRNAs has been described in tamoxifen resistance at the single
gene/target level, little is known about how concerted actions of miRNAs targeting biological networks contribute
to resistance. Here we identified the miRNA cluster, C19MC, which harbours around 50 mature miRNAs, to be
up-regulated in resistant cells, with miRNA-519a being the most highly up-regulated. We could demonstrate that
miRNA-519a regulates tamoxifen resistance using gain- and loss-of-function testing. By combining functional
enrichment analysis and prediction algorithms, we identified three central tumour-suppressor genes (TSGs) in PI3K
signalling and the cell cycle network as direct target genes of miR-519a. Combined expression of these target genes
correlated with disease-specific survival in a cohort of tamoxifen-treated patients. We identified miRNA-519a as a
novel oncomir in ER+ breast cancer cells as it increased cell viability and cell cycle progression as well as resistance
to tamoxifen-induced apoptosis. Finally, we could show that elevated miRNA-519a levels were inversely correlated
with the target genes’ expression and that higher expression of this miRNA correlated with poorer survival in ER+
breast cancer patients. Hence we have identified miRNA-519a as a novel oncomir, co-regulating a network of TSGs
in breast cancer and conferring resistance to tamoxifen. Using inhibitors of such miRNAs may serve as a novel
therapeutic approach to combat resistance to therapy as well as proliferation and evasion of apoptosis in breast
cancer.
© 2014 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Up to 70% of all breast cancer patients overexpress
the nuclear receptor oestrogen receptor-α (ER-α) [1],
making it an excellent candidate for endocrine ther-
apy. Tamoxifen is an ER antagonist that competitively
inhibits the interaction of oestrogen with the ER, thus
repressing ER activity [2, 3], and is commonly adminis-
tered in adjuvant first-line treatment of ERα+ patients.
Unfortunately, long-term efficacy has been limited by
disease relapse and the occurrence of resistance [4].
Improving response to tamoxifen and combating resis-
tance are critical and urgent priorities in current breast
cancer treatment regimes.
Tamoxifen treatment induces cell cycle arrest via
the regulation of genes such as cyclin D1, retinoblas-
toma protein (RB1), and the cyclin-dependent kinase
inhibitors CDKN1A/CIP1/WAF1/p21 and p27/KIP1
[5], and induces apoptosis by decreasing BCL2 and
increasing BAX expression [6]. Therefore, genes that
control the cell cycle and apoptosis have the potential
to impact drug sensitivity and resistance. For example,
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overexpression of cyclin D1, a direct transcriptional
target of ER signalling, conferred resistance to tamox-
ifen in vitro [7] and was up-regulated in de novo
tamoxifen-resistant cells [8]. Similarly, a recent screen
by Gonzalez-Malerva et al determined negative regula-
tors of the cell cycle to be down-regulated in tamoxifen
resistance [9]. Thus, combinatorial targeting of cell
cycle genes may be a potential route to overcome
resistance.
MicroRNAs (miRNAs) are 20- to 22-nucleotide-long
non-coding RNAs which mostly anneal in the 3′UTR
of protein coding mRNAs at sequences that have
imperfect or perfect complementarity, leading to
post-transcriptional silencing or mRNA degradation,
respectively, of the target genes. Each miRNA can
have thousands of target genes, determined by their
seed sequence at 2–8 nucleotides. Up to 50% of mam-
malian miRNAs are found in clusters, which are often
(a) (d)
(b)
(c) (f)
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Figure 1. C19MC is up-regulated in TamR cells and miRNA-519a regulates tamoxifen resistance. (a) The C19MC locus comprises
approximately 50 mature miRNAs and spans 100 kb on chromosome 19q13.42 bordered by genes DPRX distal and NLRP12, as well as
the unrelated miR-371-3 cluster, proximal. (b) Heat map showing 18 members of the miRNA cluster C19MC, depicted with an orange bar,
which are up-regulated in MCF-7 TamR cells. miR-519a is boxed in red. (c) qRT-PCR validation of the up-regulation of selected C19MC
members in TamR cells compared with WT cells, normalized to RNU44 and RNU48. (d) Overexpressing miRNA-519a in WT cells using mimics
or an overexpressing vector (e) confers resistance to tamoxifen after 72 h, while (f) inhibition of miRNA-519a in TamR cells sensitizes cells
to tamoxifen treatment. All results are shown as an average of three biological and three technical replicates. One asterisk (*) denotes a p
value of less than 0.05, two (**) denote p < 0.01, and three (***) denote p < 0.001, determined by a two-sided t-test, hereafter.
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co-transcribed from one promoter as a polycistronic
miRNA precursor [10]. There has been a recent surge
of evidence linking miRNAs and resistance to can-
cer therapy [11]. Recently, our group uncovered the
involvement of miRNA-375 in resistance to tamox-
ifen. Using our in vitro model of tamoxifen resistance,
we demonstrated that miRNA-375 regulated tamox-
ifen resistance and associated EMT-like properties,
partially through targeting the oncogene metadherin
(MTDH) [12]. While the role of a few miRNAs has
been described in tamoxifen resistance at the single
gene/target level [12,13], little is known about how
concerted actions of miRNAs contribute to resistance.
miRNAs have great therapeutic potential, due to their
ability to simultaneously co-repress many target genes.
Work from our group and others has demonstrated the
global effect of miRNAs and their ability to co-regulate
proteins within a functional network [14,15]. Since the
emergence of drug resistance is multifactorial, miR-
NAs in combination with targeted therapies may be a
potential strategy to overcome resistance.
In the present study, we identified a large cluster
of miRNAs, C19MC, which were up-regulated in
tamoxifen-resistant cells. We showed that inhibition
of miRNA-519a sensitized tamoxifen-resistant (TamR)
cells to tamoxifen, while overexpressing the miRNA
in wild-type (WT) cells conferred resistance to tamox-
ifen. We identified three tumour-suppressor genes
(TSGs) acting in the cell cycle and PI3K pathway
as direct targets of miRNA-519a. Finally, elevated
miRNA-519a levels correlated inversely with the
expression of the target genes and correlated posi-
tively with poorer disease-free survival, exclusively in
ER+ patients.
Materials and methods
Cell culture
Cells were cultured as previously described [12].
Briefly, MCF-7 WT and TamR cells were maintained in
MEM without phenol red, supplemented with 10%
FBS, 1% Pen/Strep, 1% L-glutamine, and 1% sodium
pyruvate (Invitrogen, Carlsbad, CA, USA). MCF-7
TamR cells were cultured in 5 μM 4-hydroxytamoxifen
(Sigma Aldrich, St Louis, MO, USA). HEK-293FT
cells (Invitrogen) were grown in DMEM high-glucose
medium containing 10% FBS, 1% Pen/Strep, and
500 μg/ml Geneticin. BT-474 and CAMA-1 (ATCC,
Wesel, Germany) were grown in DMEM and T-47D
was grown in RPMI-1640, respectively supplemented
with 10% FBS and 1% Pen/Strep. Medium without
antibiotics was used for transfection. MCF-7 WT and
TamR cells were cultured between passages 100 and
120, as it takes 1 year to develop the resistant cells.
Other cell lines were cultured between passages 5 and
20. Multiplex human cell authentication as well as
contamination tests of the cell lines were routinely
performed at the DKFZ Core Facility.
Transfections with miRNA mimics, inhibitors,
miRNA expression vectors, and siRNAs
Cells were seeded in full growth medium. After 24 h,
medium was replaced with medium without antibiotics.
miRNA mimics (Dharmacon, Lafayette, CO, USA),
miRCURRY LNA microRNA inhibitors (Exiqon,
Vedbaek, Denmark), miRNA-overexpression vectors
pCMV-MIRs (Origene, Oxon, UK), and siRNAs (Dhar-
macon, Lafayette, CO, USA) were transfected to a final
concentration of 25 nM, 50 nM, 25 ng/ml, and 20 nM,
respectively, using Lipofectamine 2000 transfection
reagent (Invitrogen). Combination siRNA knockdowns
were transfected to a final concentration of 20 nM.
For silencing of RB1, PTEN, and CDKN1A, pools of
four small interfering RNAs (siRNAs) were used (for
sequences, see Supplementary Table 3).
Quantitative RT-PCR for protein-coding genes
and miRNAs
qRT-PCR for mRNA and miRNAs was carried out as
previously described [16]. Sequences of primers and
the respective UPL probe numbers (Roche, Penzberg,
Germany) are given in Supplementary Table 4. ACTB,
GAPDH, and HPRT were used as mRNA housekeeping
genes, while small RNAs RNU44 and RNU48were used
as miRNA housekeeping genes. Data were analysed
using the Delta-Delta-Ct algorithm [17] (Bioconductor
ddCt package).
Cell viability and cell cycle assays
Cell viability assays were carried out as previously
described [12] using the Cell Titer Glo Luminescent
Cell Viability assay (Promega, Madison, WI, USA) fol-
lowing the manufacturer’s instructions [18]. 7-AAD and
BrdU cell cycle assays were carried out as previously
described [15] according to the manufacturer’s protocol
(BD Pharmingen San Diego, CA, USA). Stained cells
were measured by flow cytometry (FACS Calibur; BD
Biosciences, Heidelberg, Germany) using Cell Quest
Pro software (BD Biosciences).
Apoptosis assay and PI staining
Apoptosis assays were carried out using the caspase
3/7 activity assay (Promega) following the manufac-
turer’s instructions. For propidium iodide (PI) staining,
cells and medium were harvested into FACS tubes and
washed with PBS. Cells were re-suspended in 500 μl of
Nicoletti buffer containing 50 μg/ml PI (Sigma Aldrich)
and incubated for 15min [19]. Stained cells were mea-
sured by flow cytometry using Cell Quest Pro software
(BD Biosciences).
miRNA target prediction
The miRWalk database [20] was used to identify
predicted targets of miRNA-519a. 3′UTRs with a seed
match of at least 7 bases and a p value less than 0.05
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were searched for using three database algorithms:
TargetScan, PITA, and DIANA-mT.
Results
The microRNA cluster, C19MC, is up-regulated
in tamoxifen-resistant cells and one of its members,
miRNA-519a, confers tamoxifen resistance
In order to identify miRNAs which are up-regulated
upon tamoxifen resistance, we performed a miRNA
microarray and found 67 miRNAs to be significantly
up-regulated in TamR versus WT cells. C19MC,
the largest known cluster of miRNAs in the human
genome [21] encoding around 50 mature miRNAs, was
mostly up-regulated (Figures 1a and 1b). Until now,
few reports have suggested a role for this cluster in
breast cancer or drug resistance; however, studies are
emerging describing both the tumour suppressor and
oncogenic functions of these miRNAs in different can-
cer entities [22]. In total, 18 members of C19MC were
co-up-regulated in TamR cells (Figure 1b). We selected
four of the top up-regulated miRNAs from the cluster
and validated their overexpression in TamR cells with
qRT-PCR (Figure 1c). Since miRNA-519a expression
and miRNA-522 expression were both strongly induced
in TamR cells, we were interested to know if this dereg-
ulation had an impact on tamoxifen sensitivity. We first
overexpressed miRNA-519a and miRNA-522 in WT
cells using miRNA mimics. Control transfected cells
had around a 25% reduction in growth after tamoxifen
treatment (p< 0.001), while the growth of cells trans-
fected with miRNA-519a was not affected (Figure 1d),
indicating that they are no longer sensitive to tamoxifen
treatment after 72 h. However, growth of cells trans-
fected with miRNA-522 was reduced to a similar extent
to that of the control (Supplementary Figure 1), indicat-
ing that miRNA-522 may not play a role in the resistant
phenotype observed. Because miRNAmimics introduce
an unphysiologically high expression level (Supplemen-
tary Figure 2a), we employed a miRNA-overexpressing
vector system to recapitulate our results (Supplemen-
tary Figure 2b). Using the same experimental set-up
described above, pCMV–MIR-519a was also able to
confer resistance to tamoxifen (Figure 1e). Conversely,
when we inhibited miRNA-519a in TamR cells using
a synthetic inhibitor, only the growth of miRNA-519a
inhibitor-transfected cells was reduced by around 20%,
showing that TamR cells were re-sensitized to tamox-
ifen treatment (p< 0.01) (Figure 1f). Overall, these
results verified that overexpression of miRNA-519a
in WT cells confers resistance to tamoxifen, which
could be abrogated by inhibiting the miRNA in TamR
cells.
miRNA-519a targets several tumour-suppressor
genes involved in cell cycle control
As we found miRNA-519a to be an important modu-
lator of tamoxifen resistance, we were next interested
to identify target genes of the miRNA which may have
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Figure 2. Validation of CDKN1A, RB1, and PTEN as direct targets of miRNA-519a. (a) qRT-PCR reveals that predicted targets of miRNA-519a
are down-regulated in TamR cells. (b) Predicted targets are down-regulated 48 h after transfection with mimic in WT cells at RNA as well
as protein levels and (c) up-regulated after 48 h transfection with inhibitor in TamR cells. (d) mRNA structure of target genes showing the
predicted target sites of miRNA-519a in the respective 3′UTRs. (e) Luciferase assays show that the activity of each 3′UTR is reduced when
WT (e), TamR (f), and HEK 293FT (g) cells are transfected with miRNA-519a compared with control. The signal is rescued after mutating
the binding site for miRNA-519a. (h) Luciferase signal when TamR cells are transfected with miR-519a inhibitor. Luciferase signal was
normalized to empty vector. All results are shown as an average of three biological and three technical replicates, with significance levels
explained in Figure 1.
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been involved in the acquisition of resistance. Using a
combination of miRNA target prediction algorithms:
Target Scan, PITA, DIANA-mT and miRWalk [20], we
generated a list of 1704 predicted target genes. Next, we
used the functional enrichment tool DAVID [23] to iden-
tify common deregulated pathways within these 1704
potential target genes, by KEGG (Kyoto Encyclopedia
of Genes and Genomes) analysis, within the DAVID
tool (Supplementary Table 1). We found ‘Pathways
in Cancer’ to be the most enriched pathway (Supple-
mentary Table 1), containing 49 of the predicted target
genes. From these 49 genes, five were part of PI3K–Akt
signalling and seven belonged to the cell cycle pathway,
within the ‘Pathways in Cancer’ module (Supple-
mentary Table 2). We focused on these two pathways
because both have previously been strongly implicated
in tamoxifen resistance in separate contexts [24,25].
Furthermore, because we identified miRNA-519a as a
potential oncomir in TamR cells, we hypothesized that
its target genes may have a tumour-suppressive function.
Thus, we chose the well-known tumour-suppressor gene
(TSG), PTEN, within the PI3K–Akt pathway and the
negative regulators of the cell cycle, CDKN1A/p21
and retinoblastoma protein (RB1), to validate as direct
targets of miRNA-519a.
Initially, we validated that all three predicted target
genes were down-regulated in TamR cells compared
with WT cells (Figure 2a). Next, we analysed the
expression of the target genes after overexpressing
miRNA-519a in WT cells and inhibiting miRNA-519a
in TamR cells, respectively. In WT cells, mRNA and
protein levels were reduced for all three genes 48 h
after transfection (Figure 2b). Conversely, inhibition
of miRNA-519a in TamR cells rescued the expres-
sion of the target genes (Figure 2c), although we
did not observe a significant increase in p21 protein
level. We then analysed the 3′UTRs of each target
gene (Figure 2d) and found that PTEN contained two
target sites of miRNA-519a in its 3′UTR; one site
was conserved (413–419) and the other one was not
(1148–1155). For CDKN1A and RB1, there was one
predicted target site of the miRNA (Figure 2d). To
determine whether the reduced expression was due to
direct targeting by miRNA-519a, we cloned reporter
constructs containing the 3′UTR of each gene down-
stream of a luciferase reporter gene (Supplementary
Table 5). Overexpression of miRNA-519a in both WT
and TamR cells significantly reduced luciferase activity
for all three genes, which was rescued by mutating
the respective interaction sites of miRNA-519a by
site-directed mutagenesis (Figures 2e and 2f). Fur-
thermore, in order to show that these miRNA–target
interactions are not breast cancer-specific, we trans-
fected HEK 293FT cells (human embryonic kidney
cells) and repeated the luciferase reporter assays. We
obtained very similar results to the case of MCF-7
WT and TamR cells (Figure 2 g), except for RB1.
Conversely, we observed an increase in luciferase
activity when miR-519a was inhibited in TamR cells
(a) (b)
(c)
Figure 3. Correlation analysis of miRNA-519a and its target genes in patient datasets and NCI-60 cell line panel presented as scatter plots.
miRNA-519a expression is inversely correlated with expression of target genes in two patient datasets consisting of 208 patients [26] (a)
and 101 patients [27] (b), as well as in the NCI-60 cell line panel (http://dtp.nci.nih.gov/index.html; experiment ID: 372685) (c).
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(Figure 2 h). Finally, in order to examine the patho-
logical relevance of miRNA–target interactions, we
carried out a correlation analysis of miRNA-519a and
its target genes in patients and cell lines using publically
available data sets from the Gene Expression Omnibus
(GEO) (see the Materials and methods section) and the
NCI-60 cancer cell line panel, representing nine dif-
ferent tumour types (http://dtp.nci.nih.gov/index.html;
experiment ID: 372685). In the dataset GSE22220 [26],
comprising 208 breast cancer patients, the expression
of PTEN significantly correlated inversely with that of
miRNA-519a (p= 0.0389) (Figure 3a). In GSE19783
[27], miRNA-519a significantly correlated inversely
with RB1 in 101 patients (p= 0.027, Figure 3b). Finally,
in a panel of 60 cell lines of nine different cancer
origins, RB1 and CDKN1A had significant inverse
correlations (p= 0.05 and p= 0.009, respectively) with
miRNA-519a expression (Figure 3c).
miRNA-519a co-targets genes that are involved
in tamoxifen response both in vitro and in
tamoxifen-treated patients
Little is known about how concerted actions of miRNAs
targeting biological networks contribute to drug resis-
tance. We have shown that overexpressing miRNA-519a
confers resistance to tamoxifen in WT cells. The direct
targeting of three TSGs by miRNA-519a led us to
hypothesize that down-regulating these genes in WT
cells could also confer resistance to tamoxifen. For
this purpose, we silenced CDKN1A, RB1, and PTEN
in WT cells using siRNAs (Supplementary Figure 4).
Individual knockdown of either CDKN1A or RB1
or PTEN could only partially phenocopy the effects
observed on resistance to tamoxifen after overexpres-
sion of miRNA-519a (Figure 4a). This suggested that
regulation of tamoxifen resistance is likely multifacto-
rial. To investigate this hypothesis, we used a double
knockdown approach [28]. Combinatorial knockdown
of either CDKN1A and PTEN or CDKN1A and RB1
was indeed more efficient in phenocopying the effect
of miRNA-519a on tamoxifen sensitivity (Figure 4b).
However, the combination of PTEN and RB1 knock-
down did not confer resistance to tamoxifen, indicating
that CDKN1A is an essential mediator of this process.
Since we identified important regulators of the cell cycle
and PI3K signalling as direct targets, we hypothesized
that miRNA-519a could be able to co-regulate a net-
work of proteins in TamR cells, supporting the concept
of combinatorial targeting of several genes, as we have
previously demonstrated for the EGFR-driven cell cycle
[15]. Indeed, when we created a network from the pre-
dicted target genes in the KEGG ‘Pathways in Cancer’
(Supplementary Table 1), we found the three direct tar-
get genes, CDKN1A, RB1, and PTEN, to form a central
core within this network (Supplementary Figure 3).
To test the potential clinical relevance of such a
co-regulation in breast cancer patients, we carried out
(a)
(c) (d)
(b)
Figure 4. Target genes of miRNA-519a co-operatively regulate tamoxifen resistance. Inhibiting individual (a) and combinations (b) of the
TSGs using siRNAs in WT cells promotes resistance to tamoxifen after 72 h. Results are shown as an average of three biological and three
technical replicates, with significance levels explained in Figure 1. (c) Random survival forests (RSF) analysis of 632 (d) and 586 breast
cancer patients who had received hormone therapy (HT) [30] reveals a significant correlation between survival and expression of target
genes.
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(a) (b) (c)
(d)
(e) (f)
Figure 5. miRNA-519a effects on viability and cell cycle. (a) Viability of MCF-7 WT cells was measured 48 and 72 h after transfection with
miR-control or miRNA-519a. 7-AAD (b) and BrdU (c) staining was measured 72 h after transfection with miR-control or miRNA-519a to
assay cell cycle phases. The S-phase population is gated in the red box for BrdU-positive cells. (d–f) Cell viability and cell cycle assays
similar to a–c except that empty vector, pCMV-MIR or pCMV–MIR-519a overexpressing miRNA-519a were transfected as indicated. The
results are presented as an average of two biological and three technical replicates, with significance levels explained in Figure 1.
a random survival forests (RSF) analysis [29] on a
large cohort of tamoxifen-treated patients, combining
the three target genes of miRNA-519a. We extracted
gene expression data from the METABRIC study on
around 2000 primary breast tumours with long-term
clinical follow-up data [30]. Next, we selected only
patients who had received hormonal therapy (HT), ie
tamoxifen. In both the discovery (n= 632) and the
validation sets (n= 586) from this study, we found that
the patients in the poor outcome group had significantly
lower expression levels of RB1, CDKN1A, and PTEN
compared with the patients in the group of good sur-
vival outcome (Figures 4c and 4d), demonstrating the
impact of the co-regulation of these target genes in
ER+ tamoxifen-treated patients.
miRNA-519a increases viability and S-phase
population of the cell cycle, but does not affect
EMT or invasion
After identifying key TSGs co-regulated by miRNA-
519a in breast cancer, we hypothesized that overex-
pressing the miRNA would functionally affect cell
proliferation. To this end, we measured cell viability
after transfection with the miRNA-519a mimic in WT
MCF-7 cells. Indeed, in miRNA-519a-transfected cells,
there was a significant increase in viability after 48
(p< 0.01) and 72 h (p< 0.01) (Figure 5a) which was
accompanied by a significant reduction of cells in the
G1 phase, as measured by 7AAD (Figure 5b), and an
increase of cells in the S phase, measured by BrdU stain-
ing after 72 h (Figure 5c). These results were validated
using the overexpressing vector, pCMV–MIR-519a
(Figures 5d–5f). In order to show that this effect
was not restricted to MCF-7 cells, we reproduced
the effects of miR-519a overexpression in three addi-
tional ER+ cell lines, T-47D, BT-474, and CAMA-1
(Supplementary Figure 5).
We previously determined that TamR cells underwent
EMT and gained invasive properties [12]. We thus
wanted to test whether miRNA-519a could also regulate
these processes in tamoxifen resistance. To this end,
we transfected WT MCF-7 cells with miRNA-519a and
tested their invasive capacity. However, miRNA-519a
had no significant impact on invasion as similar numbers
of invading cells were counted in the control (Supple-
mentary Figure 6). In addition, there was no difference
in miRNA-519a expression when comparing epithelial
and mesenchymal cell lines from the NCI-60 panel
(not shown). Taken together, these data suggest that
miRNA-519a regulates resistance to tamoxifen through
cell proliferation; however, it is not involved in the estab-
lishment of mesenchymal-like properties of the cells.
miRNA-519a-expressing cells evade
tamoxifen-induced apoptosis
As well as inhibiting proliferation and cell cycle
progression, tamoxifen exerts its effects through the
induction of apoptosis. Reports have suggested that in
vitro models of tamoxifen resistance show increased
resistance to apoptosis induction, even at high concen-
trations [31]. When we treated WT and TamR cells
with 5 μM tamoxifen, little apoptosis was induced in
either cell type, as measured by the activity of caspase-3
and -7 (Figure 6a). However, when we treated them
with a higher dose of tamoxifen (10 μM), in line with
other studies [32,33], TamR cells remained resistant,
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Figure 6. miRNA-519a reduces tamoxifen-induced apoptosis. (a) Caspase activity is elevated only in WT cells after 3 h treatment with 10 μM
tamoxifen. (b) Caspase activity is increased only in miR-control transfected cells and is abrogated by transfection with a miRNA-519a mimic.
(c) PI staining reveals that more apoptotic cells are present in miR-control than in miRNA-519a mimic-transfected cells after 72 h treatment
with tamoxifen. (d) Caspase activity is increased only in inhibitor 519a-transfected TamR cells. The results are presented as an average of
two biological and three technical replicates each, with significance levels explained in Figure 1.
while WT cells displayed a significant induction of
apoptosis (Figure 6a). Since miRNA-519a strongly
induces cell proliferation, we hypothesized that this
would correlate with a reduction in apoptosis. To test
this, we transfected WT cells with miRNA-519a and
again treated the cells with 5 and 10 μM tamoxifen.
Caspase activity was significantly increased by around
40% (p< 0.001) in control transfected cells treated
with 10 μM tamoxifen, while miRNA-519a-transfected
cells were only slightly affected (Figure 6b). To confirm
these results after 72 h of treatment, we stained the cells
with propidium iodide. In line with the caspase activity,
cells that had been transfected with miRNA-519a had
a significantly lower apoptotic population (10% and
18%) compared with control cells (14% and 24%) after
treatment with 5 and 10 μM tamoxifen, respectively
(Figure 6c). Conversely, when we inhibited miR-519a
expression in TamR cells, caspase 3/7 activity was
significantly increased after treatment with 10 μM
tamoxifen (p< 0.01; Figure 6d). Taken together, in
addition to enhancing cell cycle and viability via the
targeting of key TSGs, miRNA-519a is capable of
evading tamoxifen-induced apoptosis. Both processes
confirm the oncogenic potential of this miRNA in breast
cancer and additionally elucidate part of the mechanism
of resistance to tamoxifen observed.
miRNA-519a expression correlates with poor
outcome and clinicopathological features in breast
cancer patients
Since miRNA-519a was highly up-regulated in TamR
cells and little was known about its role in breast
cancer, we analysed breast cancer patients’ datasets with
respect to the potential involvement of miRNA-519a
in pathogenesis. We found that high expression of
miRNA-519a correlated significantly with poorer
survival in two independent datasets (Figure 7a and
Supplementary Figure 7a, p= 0.03). Next, we divided
patients according to ER status. In GSE19783,
miRNA-519a expression correlated even more sig-
nificantly with the outcome exclusively in ER+ patients
(p= 0.0071, Figure 7b) but not in ER− patients
(p= 0.94, Figure 7c). A similar trend was observed
in the second dataset, GSE22220, although it did not
reach statistical significance (p= 0.064, Supplementary
Figures 7b and 7c). Because miRNA-519a expres-
sion is associated more significantly with survival in
ER+ patients, this gives the miRNA prognostic poten-
tial for those patients who will potentially develop
resistance to tamoxifen and regress more quickly.
As miRNA-519a is associated with poorer survival
in breast cancer and targets several TSGs, we finally
assessed whether it was associated with other clinico-
pathological features. In line with the survival data and
our model of tamoxifen resistance, miRNA-519a was
found to be significantly more highly expressed in the
more aggressive ER− tumours in the same two datasets
(Figures 7d and 7e). We observed the same trend in a
panel of 14 breast cell lines (Figure 7f). We had previ-
ously shown that TamR cells lose their expression of ER
[12] and it is known that ER− patients have a poorer
prognosis and outcome [34]. This may further suggest a
link between ER status and miR-519a expression level;
however, there must be other factors affecting the poorer
survival of ER− patients. Finally, we found significantly
higher expression of the miRNA in high-grade tumours
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Figure 7. Increased expression of miRNA-519a is significantly correlated with poorer disease-free survival in ER+ breast cancer patients
and poor clinicopathological features in breast cancer. Patients were separated according to miRNA-519a expression (median cut-off) in
a cohort of breast cancer patients [27] and miRNA-519a expression was significantly correlated with survival (a). When patients were
further sub-classified according to ER status, miRNA-519a only correlated with survival in ER+ patients (b), but not in ER− patients (c).
miRNA-519a was found to be significantly more highly expressed in ER− patients in two patient datasets (GEO Accession GSE19783 [27]
and GSE22220 [26]) (d, e) and in 14 breast cell lines, analysed by qRT-PCR (f).
(Supplementary Figure 8). Overall, these data show that
miRNA-519a expression correlates with poor survival
outcome as well as critical clinicopathological proper-
ties in breast cancer.
Discussion
In the present study, we identified a large cluster
of miRNAs, C19MC, which were up-regulated in
TamR cells compared with their parental WT cells.
Overexpressing miRNA-519a in WT cells conferred
resistance to tamoxifen, which was mediated by the
direct co-targeting of several TSGs. Our findings indi-
cate that tamoxifen-resistant cells express miRNA-519a
at high levels, which directly represses the expression
of PTEN, RB1, and CDKN1A, central nodes of a
dense network, allowing the cells to proliferate, even
in the presence of tamoxifen (Figure 8). Our results
are supported by clinical data, where we found high
expression of miRNA-519a or low co-expression of
the target genes to correlate with poorer disease-free
survival in ER+ breast cancer patients.
Until now, there have been no reports indicating an
oncogenic role of miRNA-519a in breast cancer. Other
members of the C19MC family have been described in
cancer; however, their roles seem to differ between can-
cer entities and even within subtypes [22]. In contrast to
our findings, Abdelmohsen et al reported miRNA-519a
to reduce proliferation via the direct targeting of the
HuR RNA binding protein in various cancer cell lines
[35]. On the other hand, the oncogenic role of C19MC
miRNAs in cancer has been described. For example,
miRNA-519a was found to be up-regulated and associ-
ated with poorer survival and other clinicopathological
features in ovarian carcinoma [36]. Fornari et al recently
discovered miR-519d to be up-regulated in hepatocel-
lular carcinoma (HCC). In line with our findings, they
described the miRNA to promote proliferation, inva-
sion, and evade apoptosis [37]. In ER+ breast cancer,
Foekens et al identified miR-516-3p as part of a signa-
ture of four up-regulated miRNAs linked with tumour
aggressiveness and cell cycle progression [38]. Another
study identified C19MC members (miR-520c-3p,
miR-520 g, and miR-520 h) in a screen for biomarkers
which predict outcome in tamoxifen-treated patients
and found them to be associated with the probabil-
ity of recurrence [39]. These findings support our
results, where we found miRNA-519a to be involved in
tumourigenesis and tamoxifen resistance.
Using a functional gene enrichment tool, we iden-
tified target genes in PI3K-signalling and cell cycle
pathways. We found the cyclin-dependent kinase
inhibitor CDKN1A (p21) to be a direct target of
miRNA-519a. CDKN1A had previously been identi-
fied in a genome-wide screen for tamoxifen resistance
regulators [9], and loss of CDKN1A expression in
tamoxifen-treated patients was shown to be a factor
contributing to resistance [40]. In line with our findings,
using a screen-based approach, Wu et al identified
seven members of C19MC to regulate CDKN1A, which
in turn affected the cell cycle in choriocarcinoma cells
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Figure 8. miR-519a targets central nodes (PTEN, CDKN1A, and RB1) from PI3K and cell cycle network leading to increased proliferation
and tamoxifen resistance. A snapshot from STRING (http://string-db.org) analysis depicts how the three validated direct target genes of
miR-519a form a central connection in the network, highlighted in red.
[41]. In addition, we identified RB1, themaster regulator
of the cell cycle and a prominent TSG, as a direct target.
This finding is in line with other studies which have
found RB1 inactivation to be associated with tamoxifen
resistance and the deregulation of the RB1 pathway to be
associated with recurrence in patients who were treated
with tamoxifen [42]. Finally, we showed PTEN, the neg-
ative regulator of PI3K signalling, to be a direct target.
Aberrant PI3K signalling is a well-known factor con-
tributing to tamoxifen resistance and has led to clinical
trials testing PI3K inhibitors in combinationwith tamox-
ifen [24]. Interestingly, others have reported PTEN to be
inactivated by DNAmethylation in tamoxifen resistance
[18]. In our model, we have shown a novel epigenetic
mechanism: inactivation through miRNA-519a.
Intriguingly, we found the three TSGs co-targeted by
miRNA-519a to form the core of a dense biological net-
work (Figure 8). Our findings highlight the potential of
miRNAs to modulate phenotypes in cancer cells by syn-
ergistically targeting genes within such networks. The
combined expression of the validated target genes was
significantly associated with disease risk, highlighting
their prognostic potential in tamoxifen-treated patients.
To our knowledge, this is the first study implicating the
co-targeting effect of miRNAs in tamoxifen resistance.
Using a similar approach to our study, Cittelly et al
found miR-342 to be down-regulated in tamoxifen
resistance. They also identified a number of potential
target genes in biological pathways such as cell cycle
and apoptosis but did not validate potential co-targeting
effects [43]. We have previously highlighted the global
effects that miRNAs have in the EGFR-driven cell
cycle network, where we could show that miRNAs
can directly and indirectly co-regulate networks of
proteins [15]. Interestingly, miR-519a did not alter the
invasive phenotype of TamR cells, as we have previously
demonstrated for miR-375 [12]. This finding could be
explained by the differential target spectrum of the two
miRNAs. While miR-519a acts as an oncomir, confer-
ring tamoxifen resistance through the down-regulation
of a network of TSGs, miR-375 acts as a tumour sup-
pressor, sensitizing TamR cells to tamoxifen through the
down-regulation of MTDH. It is likely that both miR-
NAs may cooperate to modulate tamoxifen resistance,
which was beyond the scope of this study.
Taken together, we have shown that co-regulation
of several TSGs by miRNA-519a confers tamoxifen
resistance in WT MCF-7 cells through regulation of
the cell cycle and apoptosis. Furthermore, our study
defined a novel role for miRNA-519a in ER+ breast
cancer and tamoxifen resistance. Our in vitro findings
are supported by clinical data, where we found a sta-
tistically significant correlation between miRNA-519a
expression and its target genes with patient survival.
miRNA-519a or its target genes could serve as potential
predictive markers for tamoxifen resistance or might be
inhibited using synthetic antagomirs as an approach to
overcome tamoxifen resistance.
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